Displaying drugs 8101 - 8125 of 8241 in total
Cariporide
Investigational
TBC-3711
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
SNS-032
Investigational
Zenarestat
Experimental
alpha-Conotoxin VC 1.1
Investigational
G4460
Investigational
Vasomera
Investigational
RG-7795
Investigational
Vitespen
Investigational
REV131
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
PRX-07034
Investigational
Epothilone D
Investigational
Annamycin
Investigational
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Alicaforsen
Investigational
Refametinib
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
AT-527
Investigational
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
RAV12
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Methopterin
Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.
Investigational
Latiglutenase
Investigational
Displaying drugs 8101 - 8125 of 8241 in total